Med Discovery announces executive R&D promotion

2010-12-20, Med Discovery appoints Christoph Kündig as Chief Scientific Officer

Christoph Kündig served as the company’s director of R&D since the beginning of its R&D activity heading Med Discovery’s drug discovery, early preclinical and CMC operations. As CSO Dr. Kündig will manage the transition of Med Discovery’s lead projects from preclinical into early clinical development.

Back